Spero Therapeutics (SPRO) Total Liabilities (2016 - 2026)

Spero Therapeutics has reported Total Liabilities for 11 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 86.13% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 86.13% YoY), and the FY2025 full-year result was $9.9 million, down 84.64% from the prior year.
• Total Liabilities for Q1 2026 stood at $6.1 million, down from $9.9 million in the prior quarter.
• The five-year high for Total Liabilities was $83.4 million in Q1 2022, with the low at $6.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $47.3 million across 5 years, with a median of $47.7 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 238.93% — and 2026, when it tumbled 86.13%.
• Spero Therapeutics' Total Liabilities stood at $48.9 million in 2022, then jumped by 54.49% to $75.5 million in 2023, then dropped by 14.67% to $64.4 million in 2024, then plunged by 84.64% to $9.9 million in 2025, then sank by 38.5% to $6.1 million in 2026.
• The last three Total Liabilities figures came in at $6.1 million (Q1 2026), $9.9 million (Q4 2025), and $27.7 million (Q3 2025), per Business Quant data.